Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site.

Virtus (ASX:VRT) share price rallies on HY21 results – time to buy?

Virtus Health Ltd (ASX: VRT) released its half-year result for FY21 on Tuesday, with the share price rising 2.3% on the day.

Virtus Health Ltd (ASX: VRT) released its half-year result for FY21 on Tuesday, with the share price rising 2.3% on the day.

Virtus Health is the largest provider of assisted reproductive services in Australia and Ireland.

Virtus’ half-year result

Virtus presented a solid set of numbers for the first half of FY21, with strong growth compared to the prior corresponding period (pcp) of HY20.

Revenue grew 19.4% to $169.9 million, adjusted EBITDA jumped 28.1% to $49.7 million and net profit after tax (NPAT) came in at $29.9 million, up 99.3% compared to the pcp.

Virtus was pleased to advise that despite the COVID-19 pandemic, growth was recorded across all key markets.

For the six months to December 2020, Australian and international fresh cycle volumes were up 18% and 15.5%, respectively, on the pcp.

Diagnostics and day hospital revenue both grew strongly, rising 9.7% and 37.5%, respectively. Day hospital revenue growth was driven by increased demand for non-IVF procedures and higher IVF volumes.

Managements comments

Commenting on the result, Virtus Health Group CEO, Kate Munnings, said: “We have experienced record levels of activity since restarting in mid-2020, demonstrating the resilience of assisted reproductive services. The Government support provided across multiple countries, allowed the preservation of our highly skilled workforce and enabled us to swiftly recommence providing safe and effective services to people who wish to become parents”.

Growth outlook

While pleased with the first-half results, Virtus expects a “normalisation of growth rates” in the second half of FY21.

Although no specific guidance was provided, Virtus stated growth will be impacted by factors including consumer sentiment, levels of international travel, COVID-19 lockdowns and the effectiveness of vaccination rollouts.

Are Virtus shares a buy for dividends?

Virtus declared a fully franked interim dividend of 12 cents per share, consistent with the pcp.

At the current share price, Virtus shares trade on a trailing dividend yield of 3.8%. This represents a higher dividend yield than that of Australia’s largest bank, Commonwealth Bank of Australia (ASX: CBA).

For the dividend-minded investor, Virtus shares appear to be a reasonable option, especially given the growth the business delivered in the first half.

For more dividend share ideas, check out Rask Media’s ASX dividend shares hub.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content